incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
=== Charge-exchange chemical ionization === This is also similar to CI and the difference lies in the production of a radical cation with an odd number of electrons. The reagent gas molecules are bombarded with high energy electrons and the product reagent gas ions abstract electrons from the analyte to form radical cations. The common reagent gases used for this technique are toluene, benzene, NO, Xe, Ar and He. Careful control over the selection of reagent gases and the consideration toward the difference between the resonance energy of the reagent gas radical cation and the ionization energy of the analyte can be used to control fragmentation. The reactions for charge-exchange chemical ionization are as follows.
The 1980s saw several new technologies that promised to change the way creatinine testing was done. Enzymatic and ion-exchange methods provided better accuracy but had other drawbacks. Enzymatic methods reduced some interferences but other new ones were discovered. High-performance liquid chromatography, HPLC, was more sensitive and specific, and had become the new reference method endorsed by the American Association for Clinical Chemistry. HPLC addressed the shortcomings of Jaffe-based methods, but was labor-intensive, expensive, and therefore impractical for routine analysis of the most frequently ordered renal analyte in medical labs. Simple, easily automated and cost-effective, Jaffe-based methods have persisted into the 21st century, despite their imperfections. By 2006, isotope dilution mass spectrometry (IDMS) became the reference method. To improve the accuracy in creatinine testing, new standards were developed by the National Institute of Standards and Technology (NIST). The College of American Pathologists (CAP) and the National Kidney Disease Education Program (NKDEP) collaborated with NIST to develop a new control reference called standard reference material 967 (SRM 967). SRM 967 aims to standardize calibration of creatinine testing, including Jaffe methods. Use of both IDMS and SRM 967 are currently recommended by the National Institutes of Health.
1993/851) Value Added Tax (General) (Amendment) (No.3) Regulations 1993 (S.I. 1993/856) Social Security (Industrial Injuries and Adjudication) Regulations 1993 (S.I. 1993/861) Social Security (Industrial Injuries) (Prescribed Diseases) Amendment Regulations 1993 (S.I. 1993/862) Official Secrets (Prohibited Places) (Amendment) Order 1993 S.I. 1993/863) Devon and Cornwall Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/864) West Mercia Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/865) Sussex Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/866) Avon and Somerset Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/867) Thames Valley Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/868) South Wales Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/869) Education (Designated Institutions in Further and Higher Education) (Interpretation) (Amendment) Order 1993 (S.I. 1993/870) A13 Trunk Road (Newham, Barking and Dagenham, and Havering) (Speed Limits) Order 1988 (Variation) Order 1993 (S.I. 1993/871) Western Isles Islands Council (Lochmaddy) Water Order 1993 (S.I. 1993/872) Oil Related and Petrochemical Plants (Rateable Values) (Scotland) Order 1993 (S.I. 1993/873) Electricity Generators (Rateable Values) (Scotland) Order 1993 (S.I. 1993/874) Scottish Hydro-Electric plc. (Rateable Values) (Scotland) Order 1993 (S.I. 1993/875) Industrial and Freight Transport (Rateable Values) (Scotland) Order 1993 (S.I. 1993/876) Scottish Nuclear Limited (Rateable Values) (Scotland) Order 1993 (S.I. 1993/877) Scottish Power plc.
Potassium alum is used in medicine mainly as an astringent (or styptic) and antiseptic. Styptic pencils are rods composed of potassium alum or aluminum sulfate, used topically to reduce bleeding in minor cuts (especially from shaving) and abrasions, nosebleeds, and hemorrhoids, and to relieve pain from stings and bites. Potassium alum blocks are rubbed over the wet skin after shaving. Potassium alum is also used topically to remove pimples and acne, and to cauterize aphthous ulcers in the mouth and canker sores, as it has a significant drying effect to the area and reduces the irritation felt at the site. It has been used to stop bleeding in cases of hemorrhagic cystitis and is used in some countries as a cure for hyperhidrosis. It is used in dentistry (especially in gingival retraction cords) because of its astringent and hemostatic properties. Potassium and ammonium alum are the active ingredients in some antiperspirants and deodorants, acting by inhibiting the growth of the bacteria responsible for body odor. Alum's antiperspirant and antibacterial properties contribute to its traditional use as an underarm deodorant. It has been used for this purpose in Europe, Mexico, Thailand (where it is called sarn-som), throughout Asia and in the Philippines (where it is called tawas). Today, potassium or ammonium alum is sold commercially for this purpose as a "deodorant crystal". Beginning in 2005 the US Food and Drug Administration no longer recognized it as a wetness reducer, but it is still available and used in several other countries, primarily in Asia.
Sources: en.wikipedia.org
There he again showed the image of parabolic patches of light on the photographic plate (see image), which suggested two species of neon nuclei with different mass-to-charge ratios. He wrote "There can, therefore, I think, be little doubt that what has been called neon is not a simple gas but a mixture of two gases, one of which has an atomic weight about 20 and the other about 22. The parabola due to the heavier gas is always much fainter than that due to the lighter, so that probably the heavier gas forms only a small percentage of the mixture." F. W. Aston subsequently discovered multiple stable isotopes for numerous elements using a mass spectrograph, related to Thomson's method. In 1919 Aston studied neon with sufficient resolution to show that the two isotopic masses are very close to the integers 20 and 22, and that neither is equal to the known molar mass (20.2) of neon gas. This is an example of Aston's whole number rule for isotopic masses, now known to be exceptionless, which states that large deviations of elemental molar masses from integers are due to the fact that the element is a mixture of isotopes. Aston similarly showed in 1920 that the molar mass of chlorine (35.45) is a weighted average of the almost integral masses for the two isotopes 35Cl and 37Cl.
=== Humans === Cocaine and other local anesthetics are known to produce cardiotoxicity by blocking sodium channels. However, no reports have been published of these same effects of cardiotoxicity associated with dimethocaine. There has been little research about toxicity of dimethocaine in humans, and therefore the exact lethal or pharmacological doses are unknown.
Though originally planned to be presented at a ceremony at the Queen Elizabeth Hall in London, the event was instead presented as a live stream on 2 April 2020 due to concern over the COVID-19 pandemic.
Sources: en.wikipedia.org
In 1923, the International Committee on Chemical Elements officially declared the atomic number to be the distinguishing quality of a chemical element. Beginning around 1913, the concept that alpha particles emerged from the atomic nucleus lead to the idea that these particle were present in the nucleus. When Van den Broek noted that the alpha particle scattering data across different elements followed atomic number and not atomic weight, he concluded that the nucleus must also have electrons. This "nuclear electron hypothesis" would be the basis of the earliest nuclear physics models. It could account for stability of alpha particles and for the then newly discovered isomers. It fueled numerous models of the nucleus as a combination of protons and electrons before finally being disproven when the neutron was discovered.
=== Recurring === Kaitlin Olson as Deborah "DJ" Vance Jr., Deborah's daughter who sells personal crafts Chris McDonald as Marty Ghilain, CEO of the Palmetto Casino Paul W. Downs as Jimmy LuSaque Jr., Deborah and Ava's manager Rose Abdoo as Josefina, Deborah's house manager Lorenza Izzo as Ruby, Ava's ex-girlfriend and an actress Megan Stalter as Kayla Schaeffer, Jimmy's inept assistant and boss's daughter Mark Indelicato as Damien, Deborah's personal assistant Poppy Liu as Kiki, Deborah's personal blackjack dealer and an employee at the Palmetto Johnny Sibilly as Wilson, a Vegas public water inspector and Marcus' love interest Angela E. Gibbs as Robin, Marcus' mother Jane Adams as Nina Daniels, Ava's mother Louis Herthum as Dennis Daniels, Ava's father who is recovering from a stroke Amanda Payton as Jackie, one of DJ's friends Joe Mande as Ray, a front desk clerk at the Palmetto Danielle Schneider as Rina, Marty's assistant Lauren Weedman as Jo Pezzimenti, the mayor of Las Vegas
== Dangers == Scarification produces harm and trauma to the skin. Infection is common when tools are not sterilised properly. Scarification has been linked to the spread of HIV/AIDS and Hepatitis C when tools are shared between people. Body modification artists may have less experience with scarification, perhaps due to lower demand. When not desired, keloid scars may be an additional complication, although there are emerging treatment strategies for them.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.